Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force
| Autor: | Abbas Raza Syed, Aly Ahmed Abdul Rahim, Sameer Al Shammari, Dina Shrestha, AG Unnikrishnan, Abbas Orabi, Khalid Shaikh, Nikhil Tandon, Jean Claude Mbanya, Sachitha Abhayaratna, Sandeep Chaudhary, Sri Venkata Madhu, Hari Kumar Shrestha, Rakesh Sahay, Sanjay Kalra, Tint Swe Latt, Fatimah Eliana, Sarita Bajaj, Ashok Kumar Das, Zhanay Akanov, Sujoy Ghosh, Aravinthan Mahalingam, Subhankar Chowdhury, Than Than Aye, Pradeep Krishna Shrestha, Mazen Askheta, Nancy Ngugi, Fariduddin, Ali Jawa, Kaushik Ramaiya, Silver Bahendeka |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Combination therapy medicine.drug_class Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Review Article Type 2 diabetes 030204 cardiovascular system & hematology lcsh:Diseases of the endocrine glands. Clinical endocrinology 03 medical and health sciences 0302 clinical medicine Endocrinology medicine Gliclazide sulfonylureas lcsh:RC799-869 Intensive care medicine Adverse effect glimepiride lcsh:RC648-665 business.industry Type 2 Diabetes Mellitus medicine.disease Sulfonylurea Glimepiride lcsh:Diseases of the digestive system. Gastroenterology type 2 diabetes business Patient education medicine.drug |
| Zdroj: | Indian Journal of Endocrinology and Metabolism, Vol 22, Iss 1, Pp 132-157 (2018) Indian Journal of Endocrinology and Metabolism |
| ISSN: | 2230-8210 |
| Popis: | For decades, sulfonylureas (SUs) have been important drugs in the antidiabetic therapeutic armamentarium. They have been used as monotherapy as well as combination therapy. Focus on newer drugs and concerns about the risk of severe hypoglycemia and weight gain with some SUs have led to discussion on their safety and utility. It has to be borne in mind that the adverse events associated with SUs should not be ascribed to the whole class, as many modern SUs, such as glimepiride and gliclazide modified release, are associated with better safety profiles. Furthermore, individualization of treatment, using SUs in combination with other drugs, backed with careful monitoring and patient education, ensures maximum benefits with minimal side effects. The current guidelines, developed by experts from Africa, Asia, and the Middle East, promote the safe and smart use of SUs in combination with other glucose-lowering drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|